期刊
INFLAMMATORY BOWEL DISEASES
卷 28, 期 SUPPL 2, 页码 S42-S44出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izac078
关键词
ustekinumab; Crohn's disease; China; treatment outcomes
资金
- China Health Promotion Foundation
Research shows that ustekinumab is more effective in treating Crohn's disease than anti-tumor necrosis factor treatment for patients who did not respond to previous treatment. The remission rates of ustekinumab are superior to those in the UNITI-1 study.
Lay Summary Ustekinumab effectively induced a clinical response and clinical remission, with remission rates superior to those in the UNITI-1 study. Ustekinumab is more effective in biologic-naive patients with Crohn's disease than those who were not responsive to anti-tumor necrosis factor treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据